|
1
|
Dauer W and Przedborski S: Parkinson's
disease: Mechanisms and models. Neuron. 39:889–909. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jenner P and Olanow CW: The pathogenesis
of cell death in Parkinson's disease. Neurology. 66 10 Suppl
4:S24–S36. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chau KY, Ching HL, Schapira AH and Cooper
JM: Relationship between alpha synuclein phosphorylation,
proteasomal inhibition and cell death: Relevance to Parkinson's
disease pathogenesis. J Neurochem. 110:1005–1013. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lees AJ, Hardy J and Revesz T: Parkinson's
disease. Lancet. 373:2055–2066. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Badger JL, Cordero-Llana O, Hartfield EM
and Wade-Martins R: Parkinson's disease in a dish-Using stem cells
as a molecular tool. Neuropharmacology. 76:88–96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dexter DT and Jenner P: Parkinson disease:
From pathology to molecular disease mechanisms. Free Radic Biol
Med. 62:132–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hernández-Romero MC, Delgado-Cortés MJ,
Sarmiento M, de Pablos RM, Espinosa-Oliva AM, Argüelles S, Bández
MJ, Villarán RF, Mauriño R, Santiago M, et al: Peripheral
inflammation increases the deleterious effect of CNS inflammation
on the nigrostriatal dopaminergic system. Neurotoxicology.
33:347–360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen H, O'Reilly EJ, Schwarzschild MA and
Ascherio A: Peripheral inflammatory biomarkers and risk of
Parkinson's disease. Am J Epidemiol. 167:90–95. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amor S and Woodroofe MN: Innate and
adaptive immune responses in neurodegeneration and repair.
Immunology. 141:287–291. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Olson KE and Gendelman HE:
Immunomodulation as a neuroprotective and therapeutic strategy for
Parkinson's disease. Curr Opin Pharmacol. 26:87–95. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Levites Y, Weinreb O, Maor G, Youdim MB
and Mandel S: Green tea polyphenol (−)-epigallocatechin-3-gallate
prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
dopaminergic neurodegeneration. J Neurochem. 78:1073–1082. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi JY, Park CS, Kim DJ, Cho MH, Jin BK,
Pie JE and Chung WG: Prevention of nitric oxide-mediated
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's
disease in mice by tea phenolic epigallocatechin 3-gallate.
Neurotoxicology. 23:367–374. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuo CL, Chen TS, Liou SY and Hsieh CC:
Immunomodulatory effects of EGCG fraction of green tea extract in
innate and adaptive immunity via T regulatory cells in murine
model. Immunopharmacol Immunotoxicol. 36:364–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoneyama S, Kawai K, Tsuno NH, Okaji Y,
Asakage M, Tsuchiya T, Yamada J, Sunami E, Osada T, Kitayama J, et
al: Epigallocatechin gallate affects human dendritic cell
differentiation and maturation. J Allergy Clin Immunol.
121:209–214. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuang X, Huang Y, Gu HF, Zu XY, Zou WY,
Song ZB and Guo QL: Effects of intrathecal epigallocatechin
gallate, an inhibitor of Toll-like receptor 4, on chronic
neuropathic pain in rats. Eur J Pharmacol. 676:51–56. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jackson-Lewis V and Przedborski S:
Protocol for the MPTP mouse model of Parkinson's disease. Nat
Protoc. 2:141–151. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei IH, Wu YC, Wen CY and Shieh JY: Green
tea polyphenol (−)-epigallocatechin gallate attenuates the neuronal
NADPH-d/nNOS expression in the nodose ganglion of acute hypoxic
rats. Brain Res. 999:73–80. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sedelis M, Schwarting RK and Huston JP:
Behavioral phenotyping of the MPTP mouse model of Parkinson's
disease. Behav Brain Res. 125:109–125. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stone DK, Reynolds AD, Mosley RL and
Gendelman HE: Innate and adaptive immunity for the pathobiology of
Parkinson's disease. Antioxid Redox Signal. 11:2151–2166. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McGeer PL and McGeer EG: Inflammation and
the degenerative diseases of aging. Ann N Y Acad Sci. 1035:104–116.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wahner AD, Bronstein JM, Bordelon YM and
Ritz B: Nonsteroidal anti-inflammatory drugs may protect against
Parkinson disease. Neurology. 69:1836–1842. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi JG, Kim HG, Kim MC, Yang WM, Huh Y,
Kim SY and Oh MS: Polygalae radix inhibits toxin-induced neuronal
death in the Parkinson's disease models. J Ethnopharmacol.
134:414–421. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hwang DS, Kim HG, Kwon HJ, Cho JH, Lee CH,
Lee JM, Jang JB, Kim YS, Lee KS and Oh MS: Dangguijakyak-san, a
medicinal herbal formula, protects dopaminergic neurons from
6-hydroxydopamine-induced neurotoxicity. J Ethnopharmacol.
133:934–939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu C, Zhang J, Shi X, Miao S, Bi L, Zhang
S, Yang Q, Zhou X, Zhang M, Xie Y, et al: Neuroprotective effects
of tetramethylpyrazine against dopaminergic neuron injury in a rat
model of Parkinson's disease induced by MPTP. Int J Biol Sci.
10:350–357. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Katiyar SK, Challa A, McCormick TS, Cooper
KD and Mukhtar H: Prevention of UVB-induced immunosuppression in
mice by the green tea polyphenol (−)-epigallocatechin-3-gallate may
be associated with alterations in IL-10 and IL-12 production.
Carcinogenesis. 20:2117–2124. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goldberg NR, Haack AK, Lim NS, Janson OK
and Meshul CK: Dopaminergic and behavioral correlates of
progressive lesioning of the nigrostriatal pathway with
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience.
180:256–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Amor S, Peferoen LA, Vogel DY, Breur M,
van der Valk P, Baker D and van Noort JM: Inflammation in
neurodegenerative diseases-an update. Immunology. 142:151–166.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bas J, Calopa M, Mestre M, Molleví DG,
Cutillas B, Ambrosio S and Buendia E: Lymphocyte populations in
Parkinson's disease and in rat models of parkinsonism. J
Neuroimmunol. 113:146–152. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dinarello CA: Historical insights into
cytokines. Eur J Immunol. 37 Suppl 1:S34–S45. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koziorowski D, Tomasiuk R, Szlufik S and
Friedman A: Inflammatory cytokines and NT-proCNP in Parkinson's
disease patients. Cytokine. 60:762–766. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dobbs RJ, Charlett A, Purkiss AG, Dobbs
SM, Weller C and Peterson DW: Association of circulating TNF-alpha
and IL-6 with ageing and parkinsonism. Acta Neurol Scand.
100:34–41. 1999. View Article : Google Scholar : PubMed/NCBI
|
